Effect of Lactoferrin Supplementation on Iron Deficiency Anemia in Primary School Children

El-Khawaga, Abeer; Abdelmaksoud, Hussein

doi:10.21608/ijma.2019.12596.1003

Cited by 6 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, as expected, treatment of study participants with twice daily doses of Lf (200 mg orally twice daily) revealed increases in serum hemoglobin level, lymphocyte count and in platelet count between control and treatment groups through treatment days. This expected laboratory indices finding is similar to prior studies [ 37 , 38 ]. The plausible explanation for this observation can be attributed to broad spectrum anti-inflammatory and anti-infective properties of Lf.…”

Section: Discussionsupporting

confidence: 93%

The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study

et al. 2021

View full text Add to dashboard Cite

Background and Objectives: Preventive, adjunctive and curative properties of lactoferrin have been evaluated since the first wave of severe acute respiratory syndrome coronavirus (SARS-CoV), a viral respiratory disease, emerged 18 years ago. Despite the discovery of new vaccine candidates, there is currently no widely approved treatment for SARS-CoV-2 (COVID-19). Strict adherence to infection prevention and control procedures, as well as vaccines, can, however, prevent the spread of SARS-CoV-2. This study aimed to evaluate the efficacy of lactoferrin treatment in improving clinical symptoms and laboratory indices among individuals with mild to moderate coronavirus disease-19 (COVID-19). Materials and Method: A randomized, prospective, interventional pilot study conducted between 8 July and 18 September 2020 used a hospital-based sample of 54 laboratory-confirmed participants with mild to moderate symptoms of COVID-19. Randomization into a control and two treatment groups ensured all groups received the approved Egyptian COVID-19 management protocol; only treatment group participants received lactoferrin at different doses for seven days. Clinical symptoms and laboratory indices were assessed on Days 0, 2 and 7 after starting treatments. Mean values with standard deviation and one-way analysis of variance with least significant difference of demographic and laboratory data between control and treatment groups were calculated. Results: Our study showed no statistically significant difference among studied groups regarding recovery of symptoms or laboratory improvement. Conclusions: Further research into therapeutic properties particularly related to dosage, duration and follow-up after treatment with lactoferrin in individuals with COVID-19 is required.

show abstract

Section: Discussionsupporting

confidence: 93%

The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The mean rises in Hb and serum iron concentration in their study were higher than those recorded in our study and this can be explained by higher doses of LF used in their study. 11 Similar results were also detected among Indian females aged 18 to 21 years, 12 where a significant increase of Hb level and serum iron was reported in cases that received LF fortified bovine colostrum once daily for 30 days and in cases that received combined therapy. The data from our study showed a significant increase in RBCs and HCT values posttherapy in group I and group III compared with group II.…”

Section: Discussionsupporting

confidence: 66%

“…This agreed with other studies that reported a significant increase in RBC and HCT values. 11,13 This improvement is attributed to improvement in serum iron concentration that was reflected by better hematogenesis and more RBC production. These speculations are supported by the fact that reticulocyte count was found to be improved posttherapy in our studied cases in the three groups compared with pretherapy, but the increase in both groups I and III was statistically higher than group II, with no statistically significant difference between group I and group III .…”

Section: Discussionmentioning

confidence: 99%

Lactoferrin Efficacy versus Ferrous Sulfate in Treatment of Children with Iron Deficiency Anemia

El-Asheer

Ahmed

Hafez

et al. 2021

Journal of Child Science

View full text Add to dashboard Cite

Lactoferrin (LF) is an iron-binding globular glycoprotein that is structurally and chemically similar to serum transferrin. Many studies have been done to evaluate the effect of oral LF administration on iron deficiency anemia (IDA) with controversial results. This study was designed to compare the efficacy of LF versus oral ferrous sulfate (OFS) therapy in the treatment of children with IDA. A significant increase in mean hemoglobin and serum iron concentrations was noted in the group that received oral bovine LF (11.06 ± 0.96 and 42.79 ± 6.14, respectively) versus the group that received OFS (10.24 ± 0.57 and 28.94 ± 5.05, respectively, with p < 0.001 for each) after 30 days of the treatment with fewer side effects (9.3 vs. 33.3% with p = 0.043). Oral bovine LF is a more effective and safer alternative in treating iron deficiency and IDA compared with OFS with clinical benefits of fewer side effects and better patient compliance.

show abstract

“…No difference in Ht, Hb, and MCV at 12 months Chen et al ( 2015a ) RDBPCT 260 exclusively-breastfed before the study, healthy infants, 4–6 months (China) 35.8 mg, formula bLF-free formula 3 months Higher Hb, ferritin, TFR-F index, and TBIC values. Lower prevalence of anemia, ID, and IDA El-Khawaga and Abdelmaksoud ( 2019 ) ROT 94 children with IDA, 6–12 years (Egypt) 200 mg Iron 30 days Increase in Hb, RBC, MCHC, serum ferritin, and serum iron Björmsjö et al ( 2020 ) RDBCT 180 healthy, formula-fed, full-term infants, 6 ± 2 weeks (Sweden) 1 g/L, formula bLF-free formula ~ 6 months of age No difference in the iron status (Hb, ferritin, MCV, and serum iron) at 4 and 6 months Chen et al ( 2020 ) RCOT 105 infants, exclusively-breastfed before the study, with anemia, 6–9 months (China) 47.2 mg, 91.5 mg, formula bLF-free formula 3 months No remarkable difference in the bLF 47.2 group. Higher Hb level in infants of the bLF 91.5 group than those in the other two groups at 3 months of intervention Mikulic et al ( 2020 ) RSBCT 26 infants without severe anemia, 3–6 months (Kenya) 1.41 g apo-bLF + FeSO 4 , 1.41 g holo-bLF FeSO 4 28 days Higher fractional iron absorption from the meal containing FeSO 4 with apo-bLF than from the meal containing FeSO 4 or holo-bLF Atia et al ( 2021 ) ROT 40 obese children with IDA, 6–18 year (Egypt) 100 mg Ferric hydroxide polymaltose 3 months Higher Hb, MCV, MCH, serum ferritin, serum iron, and transferrin saturation, and lower IL-6.…”

Section: Resultsmentioning

confidence: 99%

Clinical research review: usefulness of bovine lactoferrin in child health

Miyakawa¹,

Oda²,

Tanaka³

2022

Biometals

View full text Add to dashboard Cite

Lactoferrin (LF) is abundant in human milk and plays an important role in the health of children. Bovine LF (bLF) has high homology with human LF and has been reported to have multiple biological functions. Several clinical studies have been conducted considering these properties, which reported the usefulness of bLF. This review was aimed to provide an overview of the clinical evidence in children. We searched clinical reports investigating the effects of bLF in children and identified 36 studies on the role of bLF in infections, iron metabolism, body growth, cerebral development, and fecal microbiome. Considering the accumulated evidence, bLF may contribute to the child health, particularly by suppressing or alleviating gastrointestinal and respiratory symptoms, and improving the iron status of children with anemia or those at high risk of anemia. The dose of bLF varies depending on the expected effect and target age, but may not necessarily have to be as high as human LF in human milk. Some of the beneficial effects of bLF have not been fully validated due to limited clinical evidence or being observed in the secondary analysis of some studies. Further clinical evidence would add significant value to the use of bLF in child health.

show abstract

Effect of Lactoferrin Supplementation on Iron Deficiency Anemia in Primary School Children

Cited by 6 publications

References 11 publications

The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study

The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study

Lactoferrin Efficacy versus Ferrous Sulfate in Treatment of Children with Iron Deficiency Anemia

Clinical research review: usefulness of bovine lactoferrin in child health

Contact Info

Product

Resources

About